|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weller M, van den Bent M, Tonn JC, Stupp
R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E,
Balana C, Chinot O, et al: European Association for Neuro-Oncology
(EANO) guideline on the diagnosis and treatment of adult astrocytic
and oligodendroglial gliomas. Lancet Oncol. 18:e315–e329. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dresemann G: Temozolomide in malignant
glioma. Onco Targets Ther. 3:139–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Netto CD, da Silva AJ, Salustiano EJ,
Bacelar TS, Riça IG, Cavalcante MC, Rumjanek VM and Costa PR: New
pterocarpanquinones: Synthesis, antineoplasic activity on cultured
human malignant cell lines and TNF-alpha modulation in human PBMC
cells. Bioorg Med Chem. 18:1610–1616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Souza Reis FR, de Faria FC, Castro CP,
de Souza PS, da Cunha Vasconcelos F, Bello RD, da Silva AJ, Costa
PR and Maia RC: The therapeutical potential of a novel
pterocarpanquinone LQB-118 to target inhibitor of apoptosis
proteins in acute myeloid leukemia cells. Anticancer Agents Med
Chem. 13:341–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maia RC, Vasconcelos FC, de Sá, Bacelar T,
Salustiano EJ, da Silva LF, Pereira DL, Moellman-Coelho A, Netto
CD, da Silva AJ, Rumjanek VM and Costa PR: LQB-118, a
pterocarpanquinone structurally related to lapachol
[2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: A novel
class of agent with high apoptotic effect in chronic myeloid
leukemia cells. Invest New Drugs. 29:1143–1155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nestal de Moraes G, Castro CP, Salustiano
EJ, Dumas ML, Costas F, Lam EW, Costa PR and Maia RC: The
pterocarpanquinone LQB-118 induces apoptosis in acute myeloid
leukemia cells of distinct molecular subtypes and targets FoxO3a
and FoxM1 transcription factors. Int J Oncol. 45:1949–1958. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martino T, Magalhães FC, Justo GA, Coelho
MG, Netto CD, Costa PR and Sabino KC: The pterocarpanquinone
LQB-118 inhibits tumor cell proliferation by downregulation of
c-Myc and cyclins D1 and B1 mRNA and upregulation of p21 cell cycle
inhibitor expression. Bioorg Med Chem. 22:3115–3122. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martino T, Kudrolli TA, Kumar B, Salviano
I, Mencalha A, Coelho MGP, Justo G, Costa PRR, Sabino KCC and
Lupold SE: The orally active pterocarpanquinone LQB-118 exhibits
cytotoxicity in prostate cancer cell and tumor models through
cellular redox stress. Prostate. 78:140–151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cunha-Júnior EF, Martins TM,
Canto-Cavalheiro MM, Marques PR, Portari EA, Coelho MG, Netto CD,
Costa PR, Sabino KC and Torres-Santos EC: Preclinical studies
evaluating subacute toxicity and therapeutic efficacy of LQB-118 in
experimental visceral leishmaniasis. Antimicrob Agents Chemother.
60:3794–3801. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Sá, Bacelar T, da Silva AJ, Costa PR
and Rumjanek VM: The pterocarpanquinone LQB 118 induces apoptosis
in tumor cells through the intrinsic pathway and the endoplasmic
reticulum stress pathway. Anticancer Drugs. 24:73–83. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Faria FC, Leal ME, Bernardo PS, Costa
PR and Maia RC: NFkB pathway and microRNA-9 and −21 are involved in
sensitivity to the pterocarpanquinone LQB-118 in different CML cell
lines. Anticancer Agents Med Chem. 15:345–352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Molina JR, Hayashi Y, Stephens C and
Georgescu MM: Invasive glioblastoma cells acquire stemness and
increased Akt activation. Neoplasia. 12:453–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma L, Liu J, Zhang X, Qi J, Yu W and Gu Y:
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma
cells against TMZ. Med Oncol. 32:692015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang Z, Pore N, Cerniglia GJ, Mick R,
Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK and Maity A:
Phosphatase and tensin homologue deficiency in glioblastoma confers
resistance to radiation and temozolomide that is reversed by the
protease inhibitor nelfinavir. Cancer Res. 67:4467–4473. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Friedrich J, Seidel C, Ebner R and
Kunz-Schughart LA: Spheroid-based drug screen: Considerations and
practical approach. Nat Protoc. 4:309–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Friedrich J, Eder W, Castaneda J, Doss M,
Huber E, Ebner R and Kunz-Schughart LA: A reliable tool to
determine cell viability in complex 3-d culture: The acid
phosphatase assay. J Biomol Screen. 12:925–937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishii N, Maier D, Merlo A, Tada M,
Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of
TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shield K, Ackland ML, Ahmed N and Rice GE:
Multicellular spheroids in ovarian cancer metastases: Biology and
pathology. Gynecol Oncol. 113:143–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pelloski CE, Lin E, Zhang L, Yung WK,
Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, et al:
Prognostic associations of activated mitogen-activated protein
kinase and Akt pathways in glioblastoma. Clin Cancer Res.
12:3935–3941. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ostrom QT, Gittleman H, Truitt G, Boscia
A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors diagnosed in
the United States in 2011–2015. Neuro Oncol. 20 (Suppl 4):iv1–iv86.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stupp R, Brada M, van den Bent MJ, Tonn JC
and Pentheroudakis G; ESMO Guidelines Working Group, : High-grade
glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 25 Suppl 3:iii93–iii101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lwin Z, MacFadden D, Al-Zahrani A, Atenafu
E, Miller BA, Sahgal A, Menard C, Laperriere N and Mason WP:
Glioblastoma management in the temozolomide era: Have we improved
outcome? J Neurooncol. 115:303–310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salustiano EJ, Dumas ML, Silva-Santos GG,
Netto CD, Costa PR and Rumjanek VM: In vitro and in vivo
antineoplastic and immunological effects of pterocarpanquinone
LQB-118. Invest New Drugs. 34:541–551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
da Silva AJ, Buarque CD, Brito FV,
Aurelian L, Macedo LF, Malkas LH, Hickey RJ, Lopes DV, Noël F,
Murakami YL, et al: Synthesis and preliminary pharmacological
evaluation of new (+/-) 1,4-naphthoquinones structurally related to
lapachol. Bioorg Med Chem. 10:2731–2738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van Tellingen O, Yetkin-Arik B, de Gooijer
MC, Wesseling P, Wurdinger T and de Vries HE: Overcoming the
blood-brain tumor barrier for effective glioblastoma treatment.
Drug Resist Updat. 19:1–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baharvand H, Hashemi SM, Kazemi Ashtiani S
and Farrokhi A: Differentiation of human embryonic stem cells into
hepatocytes in 2D and 3D culture systems in vitro. Int J Dev Biol.
50:645–652. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Barbone D, Van Dam L, Follo C, Jithesh PV,
Zhang SD, Richards WG, Bueno R, Fennell DA and Broaddus VC:
Analysis of gene expression in 3D spheroids highlights a survival
role for ASS1 in mesothelioma. PLoS One. 11:e01500442016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nelson CM and Bissell MJ: Modeling dynamic
reciprocity: Engineering three-dimensional culture models of breast
architecture, function, and neoplastic transformation. Semin Cancer
Biol. 15:342–352. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hongisto V, Jernström S, Fey V, Mpindi JP,
Kleivi Sahlberg K, Kallioniemi O and Perälä M: High-throughput 3D
screening reveals differences in drug sensitivities between culture
models of JIMT1 breast cancer cells. PLoS One. 8:e772322013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fan QW and Weiss WA: Targeting the
RTK-PI3K-mTOR axis in malignant glioma: Overcoming resistance. Curr
Top Microbiol Immunol. 347:279–296. 2010.PubMed/NCBI
|
|
39
|
McNeill RS, Canoutas DA, Stuhlmiller TJ,
Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM,
Skinner KR, et al: Combination therapy with potent PI3K and MAPK
inhibitors overcomes adaptive kinome resistance to single agents in
preclinical models of glioblastoma. Neuro Oncol. 19:1469–1480.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li K, Ouyang L, He M, Luo M, Cai W, Tu Y,
Pi R and Liu A: IDH1 R132H mutation regulates glioma
chemosensitivity through Nrf2 pathway. Oncotarget. 8:28865–28879.
2017.PubMed/NCBI
|
|
41
|
Sato A, Sunayama J, Matsuda K, Seino S,
Suzuki K, Watanabe E, Tachibana K, Tomiyama A, Kayama T and
Kitanaka C: MEK-ERK signaling dictates DNA-repair gene MGMT
expression and temozolomide resistance of stem-like glioblastoma
cells via the MDM2-p53 axis. Stem Cells. 29:1942–1951. 2011.
View Article : Google Scholar : PubMed/NCBI
|
